Search results for Tibulizumab

Tibulizumab Biosimilar – Anti-IL17A, TNFSF13B, CD257 mAb – Research Grade, ProteoGenix, PX-TA1494

Description of Tibulizumab Biosimilar - Anti-IL17A, TNFSF13B, CD257 mAb - Research Grade Introduction to Tibulizumab Biosimilar – Anti-IL17A, TNFSF13B, CD257 mAb – Research Grade Tibulizumab Biosimilar is a monoclonal antibody that specifically targets three key molecules involved in inflammatory and autoimmune diseases: IL17A, TNFSF13B, and CD257. This biosimilar is a highly effective therapeutic agent that has shown promising results in pre-clinical studies and is now being developed for use in clinical trials. In this article, we will explore the structure, activity, and potential applications of Tibulizumab Biosimilar in the field of immunology. Structure of Tibulizumab Biosimilar Tibulizumab Biosimilar is a fully human monoclonal antibody, meaning it is derived from human cells and has a high affinity for its target molecules. The antibody is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of the antibody are responsible for binding to the specific targets, while the constant regions determine the effector functions of the antibody. Activity of Tibulizumab Biosimilar Tibulizumab Biosimilar targets three key molecules involved in inflammatory and autoimmune diseases: IL17A, TNFSF13B, and CD257. IL17A is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. TNFSF13B, also known as B-cell activating factor (BAFF), is a cytokine that promotes the survival and maturation of B cells, which are involved in the production of antibodies. CD257, also known as B-cell maturation antigen (BCMA), is a protein expressed on the surface of plasma cells, which are responsible for producing antibodies. By targeting these three molecules, Tibulizumab Biosimilar inhibits the inflammatory response and suppresses the production of autoantibodies, thereby reducing disease activity and progression. In addition, the antibody can also induce the death of plasma cells, further reducing the production of autoantibodies. Potential Applications of Tibulizumab Biosimilar Tibulizumab Biosimilar has shown promising results in pre-clinical studies for the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. In a mouse model of rheumatoid arthritis, treatment with Tibulizumab Biosimilar significantly reduced joint inflammation and bone destruction. In a mouse model of psoriasis, the antibody inhibited the production of pro-inflammatory cytokines and reduced skin inflammation. In a mouse model of systemic lupus erythematosus, Tibulizumab Biosimilar decreased disease activity and improved survival. In addition, Tibulizumab Biosimilar has the potential to be used in combination with other therapeutic agents for the treatment of autoimmune diseases. For example, it has been shown to enhance the efficacy of methotrexate, a commonly used drug for rheumatoid arthritis, when used in combination. Conclusion In summary, Tibulizumab Biosimilar is a highly effective monoclonal antibody that targets three key molecules involved in inflammatory and autoimmune diseases. Its unique mechanism of action, which includes inhibiting inflammatory cytokines and inducing plasma cell death, makes it a promising therapeutic agent for the treatment of various autoimmune diseases. With ongoing clinical trials, Tibulizumab Biosimilar has the potential to provide a new treatment option for patients suffering from these debilitating conditions.

Tibulizumab, Abbexa, abx831453

Tibulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL17A/TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Tibulizumab ELISA Kit, ProteoGenix, KPTX262

Description of Tibulizumab ELISA Kit The Structure and Function of Tibulizumab ELISA Kit: A Powerful Tool for Antibody Detection and Therapeutic Targeting The Basics of Tibulizumab ELISA Kit Tibulizumab ELISA Kit is a highly sensitive and specific tool used for the detection and quantification of Tibulizumab, a monoclonal antibody that targets the human CD6 receptor. The kit utilizes an enzyme-linked immunosorbent assay (ELISA) technique, which is based on the specific binding of Tibulizumab to its target antigen, CD6, in a sample. This results in a colorimetric signal that can be measured and used to determine the amount of Tibulizumab present in the sample. The Structure of Tibulizumab Tibulizumab is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity and specificity for its target antigen. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) at the ends of the arms and a crystallizable fragment (Fc) at the base. The Fab regions are responsible for binding to CD6, while the Fc region is involved in immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The Activity of Tibulizumab Tibulizumab is a potent inhibitor of CD6, a cell surface glycoprotein that is primarily expressed on T cells. CD6 plays a crucial role in T cell activation, differentiation, and proliferation, making it an attractive therapeutic target for various autoimmune and inflammatory diseases. Tibulizumab binds to CD6 on T cells, preventing its interaction with its ligand, CD166, and disrupting downstream signaling pathways. This leads to the inhibition of T cell activation and cytokine production, ultimately reducing inflammation and tissue damage. The Application of Tibulizumab ELISA Kit Tibulizumab ELISA Kit has a wide range of applications in both research and clinical settings. In research, the kit can be used to measure the levels of Tibulizumab in various biological samples, such as serum, plasma, and cell culture supernatants. This allows for the evaluation of Tibulizumab pharmacokinetics and pharmacodynamics, as well as the monitoring of antibody levels during clinical trials. Additionally, the kit can be used to detect and quantify Tibulizumab in preclinical studies, aiding in the development and optimization of the antibody. In the clinical setting, Tibulizumab ELISA Kit has significant implications for the diagnosis and treatment of autoimmune and inflammatory diseases. The kit can be used to measure Tibulizumab levels in patient samples, providing valuable information for dosing and treatment monitoring. It can also be used to assess the presence of anti-drug antibodies (ADA), which can impact the effectiveness of Tibulizumab therapy. Furthermore, the kit can aid in the development of personalized treatment strategies, as it allows for the identification of patients who may benefit from Tibulizumab therapy based on their levels of CD6 expression. Conclusion In summary, Tibulizumab ELISA Kit is a powerful tool for the detection and quantification of Tibulizumab, a monoclonal antibody that targets the CD6 receptor. Its high sensitivity and specificity make it a valuable tool for both research and clinical applications, providing crucial information for the development and optimization of Tibulizumab therapy. With its ability to measure Tibulizumab levels and detect ADA, the kit has the potential to improve patient outcomes and contribute to the advancement of precision medicine.

Tibulizumab ELISA Kit, Abbexa, abx395151

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Tibulizumab ELISA Kit is a quantitative ELISA kit for detection of Tibulizumab.Tibulizumab (LY-3090106) is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.

Research Grade Tibulizumab (HS856106), abinScience, HS856106